Eric Lawitz

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 8

Top Topics

Combination Therapy

Hepatitis C Virus

Top Venues

Liver international : official journal of the International Association for the Study of the Liver

Journal of viral hepatitis

Health science reports

This page only lists publications with an associated author ORCID identifier.

Publications

Rohit L Loomba, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver international : official journal of the International Association for the Study of the Liver 44 (4) (2024)
Rohit L Loomba, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver international : official journal of the International Association for the Study of the Liver 44 (4) (2024)
Rohit L Loomba, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver international : official journal of the International Association for the Study of the Liver 44 (4) (2024)
Rohit L Loomba, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver international : official journal of the International Association for the Study of the Liver 44 (4) (2024)
Rohit L Loomba, Carl LaCerte, Jeffrey Edwards, Fred Poordad, Eric Lawitz, Lois Lee, Sharon Karan, Sangeeta Sawhney, Mary Erickson, Leigh MacConell, Luna Zaru, Jianfen Chen, Jason Campagna
Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH. Liver international : official journal of the International Association for the Study of the Liver (2024)
Eric Lawitz, Fred Poordad, Julio A Gutierrez, Maria Beumont, Greet Beets, Ann Vandevoorde, Pieter Van Remoortere, Donghan Luo, Leen Vijgen, Veerle Van Eygen, Mohamed Gamil
Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health science reports 3 (2) (2020)
Eric Lawitz, Edward Gane, Jordan J Feld, Maria Buti, Graham R Foster, Mordechai Rabinovitz, Eduard Burnevich, Helena Katchman, Krzysztof Tomasiewicz, Fred Lahser, Beth Jackson, Melissa Shaughnessy, Stephanie Klopfer, Wendy W Yeh, Michael N Robertson, George J Hanna, Eliav Barr, Heather L Platt, null null
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of viral hepatitis 26 (9) (2019)
Eric Lawitz, Fred Poordad, Leah J Anderson, Michelle Vesay, Michelle M Kelly, Hong Liu, Wei Gao, Doreen Fernsler, Ernest Asante-Appiah, Michael N Robertson, George J Hanna, Eliav Barr, Joan Butterton, Kris V Kowdley, Tarek Hassanein, Amandeep Sahota, Stuart C Gordon, Wendy W Yeh
Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. Journal of viral hepatitis 26 (6) (2019)